Combined cytotoxic effects of tumor necrosis factor-α with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53

Journal of Immunotherapy

Volumn 22, Issue 1, 1999, Pages 48-53

  Sleijfer, Stefan ^a   Phuong Le, T K ^a   De Jong, Steven ^a   Timmer Bosscha, Hetty ^a   Withoff, Sebo ^a   Mulder, Nanno H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Drug resistance; Mutant p53; Tumor necrosis factor

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; MELPHALAN; MITOXANTRONE; MUTANT PROTEIN; PACLITAXEL; PROTEIN P53; TENIPOSIDE; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE;

ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; GENES, P53; HUMANS; MELPHALAN; MITOXANTRONE; MUTATION; OVARIAN NEOPLASMS; PACLITAXEL; TENIPOSIDE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VINBLASTINE;

EID: 0032947716     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199901000-00007     Document Type: Article

References (36)

1. Frei E III, Spriggs D. Tumor necrosis factor: still a promising agent. J Clin Oncol 1989;7:291-4.
2. Lejeune FJ. High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995;31:1009-16.
3. Sleijfer S, Mulder NH. Tumour necrosis factor: the decline and fall of a biological agent and its resurrection. Clin Oncol 1994;6:127-32.
4. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14: 2653-65.
5. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479-89.
6. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
7. Posner M, Lienard D, Lejeune F, Rosenfelder D, Kirkwood J. Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma. Proc Am Soc Clin Oncol 1994;13:396 (abstr. 1351).
8. Bonavida B, Tsuchitani T, Zighelboim J, Berek JS. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Gynecol Oncol 1990;38:333-9.
9. Utsugi T, Mattern MR, Mirabelli CK, Hanna N. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res 1990;50: 2636-40.
10. Safrit JF, Belldegrun A, Bonavida B. Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistance. J Urol 1993;149: 1202-8.
11. Safrit JT, Bonavida B. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res 1992;52:6630-7.
12. Valenti M, Cimoli G, Parodi S, et al. Potentiation of tumour necrosis factor-mediated cell killing by VP-16 on human ovarian cancer cell lines. In vitro results and clinical implications. Eur J Cancer 1993;29:1157-61.
13. Cimoli G, Valenti M, Parodi S, De Sessa F, Russo P. Circumvention of atypical multidrug resistance with tumor necrosis factor. Jpn J Cancer Res 1994;85:135-8.
14. Valenti M, Cimoli G, Mariani GL, Conte PF, Parodi S, Russo P. Potentiation of TNF-mediated cell killing by mitoxantrone. Biochem Pharmacol 1993;46:1199-206.
15. Alexander RB, Nelson WG, Coffey DS. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 1987; 47:2403-6.
16. Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 1993;72:809-18.
17. Baloch Z, Cohen S, Coffman FD. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II. J Immunol 1990;145:2908-13.
18. Soranzo C, Perego P, Zunino F. Effects of tumor necrosis factor on human tumor cell lines sensitive and resistant to cytotoxic drugs, and its interaction with chemotherapeutic agents. Anticancer Drugs 1990;1:157-63.
19. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
20. Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
21. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-8.
22. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 1993; 74:957-67.
23. Fan S, Smith ML, Rivet DJ II, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55:1649-54.
24. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med 1996;2:72-9.
25. Van Waardenburg RCAM, De Jong S, Withoff S, De Vries EGE, Mulder NH. Effects of wild-type or mutant p53 overexpression in a wild-type p53 ovarian tumor cell line. Proc Am Assoc Cancer Res 1997;38:273 (abstr. 1830).
26. Slavotinek A, McMillan TJ, Steel CM. Measurement of radiation survival using the MTT-assay. Eur J Cancer 1994;30:1376-82.
27. Stein U, Walther W, Shoemaker RH. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 1996;74:1384-91.
28. Baloch Z, Cohen S, Fresa K, Coffman FD. Modulation of topoisomerase activities by tumor necrosis factor. Cell Immunol 1995; 160:98-103.
29. Okamoto T, Watanabe N, Yamauchi N, et al. Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res 1992;52:5278-81.
30. Wong GHW, Elwell JH, Oberley LW, Goeddel DV. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989;58:923-31.
31. Li J-J, Oberley LW. Overexpression of manganese-containing superoxide dismutase confers resistance to the cytotoxicity of tumor necrosis factor a and/or hyperthermia. Cancer Res 1997;57: 1991-8.
32. Doroskow JH, Akman S, Esworthy S, Chu FF, Burke T. Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells. Free Radic Res Commun 1991;12:779-81.
33. Holstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-5.
34. Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects of tumor necrosis factor on sensitivity and multidrug resistant human leukemia and myeloma cell lines. Blood 1989;74:1723-7.
35. Sleijfer S, Asschert J, Timmer-Bosscha H, Meijer C, De Vries EGE, Mulder NH. Enhanced sensitivity to tumor necrosis factor-α in adriamycin-resistant cell lines. Proc Am Assoc Cancer Res 1996;37:215 (abstr. 1470).
36. Jia L, Kelsey SM, Grahn MF, Jiang XR, Newland AC. Increased activity and sensitivity of mitochondrial respiratory enzymes to tumor necrosis factor alpha-mediated inhibition is associated with increased cytotoxicity in drug-resistant leukemic cell lines. Blood 1996;87:2401-10.